Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Interest Expenses (2016 - 2023)

Historic Interest Expenses for Cartesian Therapeutics (RNAC) over the last 9 years, with Q3 2023 value amounting to $1.3 million.

  • Cartesian Therapeutics' Interest Expenses rose 5872.82% to $1.3 million in Q3 2023 from the same period last year, while for Jun 2024 it was $1.3 million, marking a year-over-year decrease of 5982.96%. This contributed to the annual value of $2.8 million for FY2023, which is 653.25% down from last year.
  • Per Cartesian Therapeutics' latest filing, its Interest Expenses stood at $1.3 million for Q3 2023, which was up 5872.82% from $752000.0 recorded in Q2 2023.
  • In the past 5 years, Cartesian Therapeutics' Interest Expenses registered a high of $1.3 million during Q3 2023, and its lowest value of $205000.0 during Q2 2020.
  • Over the past 5 years, Cartesian Therapeutics' median Interest Expenses value was $711000.0 (recorded in 2021), while the average stood at $620157.9.
  • As far as peak fluctuations go, Cartesian Therapeutics' Interest Expenses skyrocketed by 568333.33% in 2019, and later tumbled by 4875.0% in 2020.
  • Cartesian Therapeutics' Interest Expenses (Quarter) stood at $335000.0 in 2019, then skyrocketed by 112.84% to $713000.0 in 2020, then dropped by 0.28% to $711000.0 in 2021, then rose by 13.5% to $807000.0 in 2022, then surged by 57.74% to $1.3 million in 2023.
  • Its Interest Expenses was $1.3 million in Q3 2023, compared to $752000.0 in Q2 2023 and $808000.0 in Q1 2023.